Topic Archives: Inovio Pharmaceuticals (INO)

I’ve gotten a few questions about the latest Technology Profits Confidential (currently $79/yr) tease from Ray Blanco, so although it’s a few weeks old now, and started circulating right in the heat of the first coronavirus downturn in mid-March, I thought I’d take a look today. It is still a current ad, I got it […]

Having just devoted an entire Doc Gumshoe piece to the notorious coronavirus (COVID 19), Iā€™m going to make those coronavirus updates brief ā€“ it looks to me as though the news media is devoting a major part of its capacity to covering most aspects of this pandemic ā€“ and, yes, it now certainly looks like […]

Stansberry Venture is a high-end ($5,000/yr) newsletter that focuses on small “breakthrough” type companies, so far mostly in biotech and technology as far as I’ve seen. It’s the heir, roughly speaking, of Stansberry’s old Phase 1 newsletter that used to often pitch biotech, tech and junior mining stocks. It’s helmed by Dave Lashmet, who was […]

Comments

  • Avatar

    INO has crashed and burned with announcement of huge investor lawsuit....

  • Gr8Full!

    $ONCS reduced to skeletal 20180124 - When the geauxing gets tough, the tough get geauxing.... $ARTH ow, $INO sp - I...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch